Lu-177 HA-DOTATATE for Peptide Receptor Radionuclide Therapy (PRRT): First Results in Patients Concerning Biodistribution, Normal Organ and Tumor Dosimetry

被引：0
|
作者：
Schuchardt, C. [1 ]
Kulkarni, H. R. [1 ]
Wiessalla, S. [1 ]
Shahinfar, M. [1 ]
Shafaei, S. [1 ]
Kropf, S. [2 ]
Wester, H. J. [3 ,4 ]
Baum, R. P. [1 ]
机构：
[1] Zent Klin Bad Berka GmbH, THERANOST Ctr Mol Radiotherapy & Mol Imaging, Bad Berka, Germany
[2] Scintomics GmbH, Fuerstenfeldbruck, Germany
[3] Tech Univ Munich, Fac Chem, D-80290 Munich, Germany
[4] Tech Univ Munich, Fac Med, D-80290 Munich, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2014年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP290
引用
收藏
页码：S224 / S224
页数：1
相关论文
共 50 条
  • [11] PRRT using the radiolabelled somatostatin receptor antagonist Lu-177 DOTA-LM3: First Results of biodistribution and dosimetry in comparison with Lu-177 DOTATOC
    Schuchardt, C.
    Kulkarni, H. R.
    Wiessalla, S.
    Far, M. Shahin
    Singh, A.
    Langbein, T.
    Lehmann, C.
    Fani, M.
    Maecke, H.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S589 - S589
  • [12] First comparative dosimetric results after peptide receptor radionuclide therapy (PRRT) using Lu-177 DOTA-NOC and Lu-177 DOTA-TATE
    Wehrmann, C.
    Senftleben, S.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S179 - S179
  • [13] Peptide Receptor Radionuclide Therapy (PRRT) Using 177Lu-DOTATATE: Early Clinical and Dosimetric Results
    Garkavij, M.
    Nickel, M.
    Sjogreen-Gleisner, K.
    Ljungberg, M.
    Strand, S. E.
    Ohlsson, T.
    Tennvall, J.
    NEUROENDOCRINOLOGY, 2009, 90 (01) : 113 - 113
  • [14] Peptide receptor radionuclide therapy (PRRT) using 177Lu-Dotatate:: Early clinical and dosimetric results
    Garkavij, M.
    Sjogreen-Gleisner, K.
    Nickel, M.
    Ohlsson, T.
    Wingardh, K.
    Tennvall, J.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2008, 23 (04) : 524 - 525
  • [15] The technologist role in 177Lu dosimetry for PRRT (Peptide Receptor Radionuclide Therapy)
    Leoni, E.
    Filice, A.
    Palmieri, A.
    Ghiraldini, G.
    Fioroni, F.
    Grassi, E.
    Cola, S.
    Versari, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S850 - S851
  • [16] Dosimetry in Lu-177-DOTATATE peptide receptor radionuclide therapy: a systematic review
    Nautiyal, Amit
    Michopoulou, Sofia
    Guy, Matt
    CLINICAL AND TRANSLATIONAL IMAGING, 2024, 12 (02) : 157 - 175
  • [17] Dosimetry in Lu-177-DOTATATE peptide receptor radionuclide therapy: a systematic review
    Amit Nautiyal
    Sofia Michopoulou
    Matt Guy
    Clinical and Translational Imaging, 2024, 12 : 157 - 175
  • [18] Dosimetry in peptide receptor Radionuclide therapy (PRRT) using Lu-177 DOTA-TATE: Intra- and interpatient variability
    Wehrmann, C.
    Senftleben, S.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S178 - S179
  • [19] SPECT/CT calibration using clinical dosimetry workstations for peptide receptor radionuclide therapy (PRRT) in patients treated with 177Lu-DOTATATE
    Mora Ramirez, E.
    Santoro, L.
    Trauchessec, D.
    Chouaf, S.
    Deshayes, E.
    Pouget, J.
    Kotzki, P.
    Bardies, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S809 - S810
  • [20] Biphasic exponential dosimetry model for 177Lu-DOTATATE peptide receptor radionuclide therapy
    Chen, Sirong
    Cheng, Kam
    Li, Ka Chun
    Leung, Yim Lung
    Cheung, William
    Wong, Ka Nin
    Wong, Yuet Hung
    Ho, Chi-Lai
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
12345